Recent news on Gonal-F

Phase III Data on Safinamide in Parkinson's Disease Presented at ...  -  May 2, 2007
PipelineReview.com (press release),The Company is the world leader in reproductive health, with Gonal-f(R), Luveris(R)and Ovidrel(R)/Ovitrelle(R). It has strong market positions in neurology,

Merck Serono SA to Voluntarily Delist and Deregister its Bearer ...  -  Apr 6, 2007
Drug Newswire (press release),The Company is the world leader in reproductive health, with Gonal-f(R), Luveris(R) and Ovidrel(R)/Ovitrelle(R). It has strong market positions in neurology

EPG Patient Direct Partners With Merck Serono To Produce Psoriasis ...  -  Mar 29, 2007
Medical News Today (press release),Neurology (Rebif®), CardioMetabolic Care (Glucophage®, Concor®), Reproductive Health (Gonal-f®), Dermatology (Raptiva®) and other therapeutic areas.

Merck KGaA Announces Serono Preliminary Figures for 2006  -  Mar 23, 2007
Drug Newswire (press release),In 2006, sales of Gonal-f(R) decreased by 2.5% to $533 million and by 1.2% to $132 million in the fourth quarter. Saizen(R) sales increased by 1.2% to $209

Merck Serono Confirms Previously Announced 2006 Figures  -  Mar 21, 2007
PharmaLive.com (press release),The Company is the world leader in reproductive health, with Gonal-f(R), Luveris(R) and Ovidrel(R)/Ovitrelle(R). It has strong market positions in neurology

Merck Serono Launches easypod(R), First Electronic Growth Hormone ...  -  Jan 30, 2007
Drug Newswire (press release),The Company is the world leader in reproductive health, with Gonal-f(R), Luveris(R) and Ovidrel(R)/Ovitrelle(R). It has strong market positions in neurology

Merck Serono Launches easypod(R), First Electronic Growth Hormone ...  -  Jan 29, 2007
Yahoo! News (press release)The Company is the world leader in reproductive health, with Gonal-f®, Luveris® and Ovidrel®/Ovitrelle®. It has strong market positions in neurology,

Selling yourself short?  -  Feb 5, 2007
Spectator Eau Claire (subscription),The injections contain Fertinex, Follistim or Gonal-f, all of which are follicle-stimulating hormone (FSH) recombinant drugs. The FSH injections stimulate

Merck Serono Completes Patient Enrollment in CLARITY Phase III ...  -  Jan 16, 2007
Drug Newswire (press release),The Company is the world leader in reproductive health, with Gonal-f(R), Luveris(R) and Ovidrel(R)/Ovitrelle(R). It has strong market positions in neurology

ZymoGenetics and Serono Begin Phase 2 Clinical Trial With ...  -  Dec 19, 2006
PR Newswire (press release),The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R)/Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R)

Merck Serono is Launched  -  Jan 8, 2007
Drug Newswire (press release),The Company is the world leader in reproductive health, with Gonal-f(R), Luveris(R) and Ovidrel(R)/Ovitrelle(R). It has strong market positions in neurology

Merck Serono is Launched  -  Jan 7, 2007
Yahoo! News (press release)The Company is the world leader in reproductive health, with Gonal-f®, Luveris® and Ovidrel®/Ovitrelle®. It has strong market positions in neurology,

Merck KGaA Acquires Majority Shareholding in Serono SA  -  Jan 5, 2007
Yahoo! News (press release)The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel(R )/Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®.

ZymoGenetics and Serono Begin Phase 2 Clinical Trial With ...  -  Dec 19, 2006
PR Newswire (press release),The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R)/Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R ...

Serono Announces Initiation of the Reflex Trial to Evaluate New ...  -  Dec 11, 2006
Yahoo! News (press release)The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel® /Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®. ...

Merck KGaA: European Antitrust Authorities Clear Acquisition of ...  -  Dec 17, 2006
Yahoo! News (press release)The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel ®/Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®. ...

Merck KGaA: European Antitrust Authorities Clear Acquisition of ...  -  Dec 18, 2006
PharmaLive.com (press release),The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel (R)/Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R ...

24-Week Clear Study Results Confirm Sustained Efficacy and Safety ...  Oct 30, 2006
The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R) /Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R ... -PR Newswire UK (press release), 24-Week Clear Study Results Confirm Sustained Efficacy And Safety ...  Oct 31, 2006
The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel®/Ovitrelle®, Serostim®, Saizen®, Zorbtiveâ„¢ and Raptiva®. ... -PipelineReview.com (press release), Serono Delivers Strong Adjusted* Net Income of $183.5m in Third ...  Oct 18, 2006
...of 2006 were $2.8m, down 84.6%, consequent to the introduction of generics of mitoxantrone in the US in April 2006 (Q3 2005: $18.2m). Sales of Gonal-f(R) were ... -PR Newswire (press release), Serono and Newron Announce Global Development and ...  Oct 15, 2006
The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel(R )/Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®. ... -Yahoo! News (press release) Serono Delivers Strong Adjusted* Net Income of $183.5m in Third ...  Oct 18, 2006
Sales of Gonal-f(R) were $122.8m in line with the third quarter of 2005 (Q3 2005: $125.6m). Global sales of supporting products (Ovidrel(R), Cetrotide(R ... -MSN Money Marking Time at Serono  Oct 19, 2006
Since Rebif and the $123 million earned from fertility drug Gonal-f account for the vast majority of Serono's sales -- more than 80% -- I like to look at these ... -Motley Fool Serono and Syntonix to Pursue the Development of a Long-Acting ...  Sep 17, 2006
Serono is the world leader in the treatment of infertility and currently markets GONAL-f® (follitropin alfa), a highly consistent recombinant human follicle ... -Yahoo! News

Merck KgaA to Acquire Serono  Sep 21, 2006
The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel(R )/Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®. ... -Yahoo! News

Serono's Oral Cladribine for the Treatment of Multiple Sclerosis ...  Sep 21, 2006
The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R )/Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R ... -PharmaLive.com

Sayonara, Serono  Sep 21, 2006
The two drugs that account for more than 80% of company sales -- Rebif for multiple sclerosis, and infertility treatment Gonal-f -- are relatively stale ... -MSNBC

Merck KGaA to buy rival Serono for $13.3 billion  Sep 21, 2006
...sales in 2005. Its other main franchise is infertility treatments, with its Gonal F drug generating 21% of sales. Merck's products ... -MarketWatch

Merck KGaA Buying Serono, Giving CHF16.6B Valuation  Sep 21, 2006
...the multiple sclerosis drug Rebif (interferon beta-1a), which generated almost $1.3 billion in sales in 2005, and the fertility drug gonal-f, which generated ... -BioWorld Online

Germany's Merck acquires Europe's largest biotech company  Sep 21, 2006
...in 2005. Its other main franchise is infertility treatments, with its Gonal F drug generating 21 per cent of sales. Merck's products ... -domain-B

BioMarin and Serono Announce Data on Phenoptin in PKU to be ...  Sep 12, 2006
The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R)/Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R ... -PR Newswire

Commie Girl  Aug 31, 2006
...this and see what God does.’� Honey, that ain’t God. That’s Repronex and Gonal-f. God had already answered you, remember? -OC Weekly

Serono Announces Initiation of the Reflex Trial to Evaluate New ...  -  12 Dec 2006
Drug Newswire (press release),The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R) /Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and

Serono Announces Results From Pivotal Phase III Clinical Trial of ...  Aug 17, 2006
The Company has seven recombinant products, Rebif(R) (interferon beta-1a), Gonal-f(R) (follitropin alfa for injection), Luveris(R) (lutropin alfa), Ovidrel ... -PR Newswire

Get the latest news direct to your desktop  Aug 18, 2006
The Company has seven recombinant products, Rebif® (interferon beta-1a), Gonal-F® (follitropin alfa for injection), Luveris® (lutropin alfa), Ovidrel ... -PipelineReview.com

Serono Delivers Second Quarter EPS of $12.92, Up 25.2% on Adjusted ...  Jul 26, 2006
...resonance imaging scans. Sales of Gonal-f® were $139.3m (Q2 2005: $149.9m), in line with the first quarter of 2006. Global sales ... -Yahoo! News

Serono Q2 net profit rises 8 pct, sales disappoint - UPDATE  Jul 27, 2006
However, sales of itsfertility drug Gonal-F dropped by 7.1 pct to 139.3 mln usd. ... Gonal-F's contribution fell from 24.5 pct to 22.2 pct. ... -Forbes

Serono Under Attack  Jul 27, 2006
Serono's other lead product, Gonal-F, a product to treat infertility, is slowly on the decline -- sales have dropped 7% to $139 million versus the second ... -Motley Fool

Serono Beats Net Pft Calls - Merrill  Jul 27, 2006
11%. Top line was a bit weak, analyst says, due to flat quarter-on-quarter Gonal-f sales. The company retained its outlook. Merrill ... -newratings.com

Serono Risk From Legal Uncertainty Eyed  Jul 27, 2006
..."In addition, the US lawsuits on inappropriate sales and marketing practices which now cover most of Serono's product line including Rebif, Gonal-f, Saizen and ... -newratings.com

Serono Q2 profit rises  Jul 27, 2006
Products key to driving growth include Rebif, which saw its sales rise 10.9% for the quarter, to reach $361.6 million, as well as Gonal-f, Saizen and Raptiva ... -Pharmaceutical Business Review

Swiss shares little higher in thin trade as financial strength ...  Jul 27, 2006
...quarter sales did not, rising 3.3 pct to 699.2 mln usd, with sales of key MS treatment Rebif strong but those of fertility treatment Gonal-F disappointing. -Forbes

Serono 2Q Net Income Rises 8 Percent  Jul 26, 2006
...rose 3.3 percent to $699.2 million, up from $678.8 million, as sales of psoriasis drug Raptiva also rose sharply while sales for fertility drug Gonal-f declined ... -Houston Chronicle

European Commission Approves Revision of Therapeutic Indication ...  Jul 9, 2006
The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel® /Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®. ... -Yahoo! News

European Commission Approves Revision of Therapeutic Indication ...  Jul 10, 2006
The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R) /Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R ... -PharmaLive.com



Serono Announces Termination of Discussions Concerning a Sale of ...  Apr 9, 2006
The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel(R )/Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®. ... - Yahoo! News

Serono Seeks Approval to Create Shares for Purchases (Update2)  Mar 30, 2006
Serono generates three-quarters of its sales from the multiple-sclerosis medicine Rebif, which was first sold in 1998, and fertility drug Gonal-f, the first ... - Bloomberg

EUROPE MARKETS  Mar 31, 2006
Novartis are among the pharmaceutical producers said to be interested in Serono, which makes the Rebif multiple-sclerosis drug and the Gonal-F infertility drug ... - Wall Street Journal (subscription)

BioMarin and Serono Announce Positive Results From Phase 3 ...  Mar 15, 2006
The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R)/Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R ... - PR Newswire

BioMarin and Serono Announce Positive Results From Phase 3 ...  Mar 15, 2006
The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel® /Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®. ... - Yahoo! News



Seronons 2005 Adjusted(i) EPS Increased by 34.6%  Feb 5, 2006
In 2005, sales of Gonal-f(R) decreased by 4.5% (-5.2% in local currencies) to $547.0m (2004: $572.7m) and by 11.7% (-9.0% in local currencies) to $133.5m in ... - MSN Money

Serono 4th-Quarter Net Misses Estimates, Sales Drop (Update4)  Feb 6, 2006
Shares of Serono, which sells the multiple sclerosis therapy Rebif and fertility drug Gonal-f, fell to their lowest level since Nov. ... - Bloomberg

Flat sales in Q4 for Serono; no word on buyer  Feb 6, 2006
...second quarter in a row at $605 million, as growth slowed for its multiple sclerosis product Rebif and sales of its fertility treatment Gonal F continued to ... - Pharma Times (subscription),

UPDATE 2-Serono sales, profits miss forecasts, mum on M&A  Feb 5, 2006
...the fourth quarter at $604.5 million, as a surge in demand for multiple sclerosis drug Rebif appeared to cool off and sales of fertility drug Gonal-F fell by ... - Reuters

Serono sales, profits miss forecasts, mum on M&A  Feb 5, 2006
...biggest biotech firm were flat in the fourth-quarter at $604.5 million, as Rebif's surge appeared to cool off and sales of fertility drug Gonal-F fell by 11.7 ... - Reuters

Swiss shares close flat tracking Wall Street; pharmas under ...  Feb 6, 2006
Morgan said normalised Q4 net income was in line with expectations, but that product sales -- most notably flagship products Rebif and Gonal-F -- were weaker ... - Forbes

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional